Adaptimmune Therapeutics (ADAP) to Release Quarterly Earnings on Wednesday

Posted by Ed Jones on Nov 9th, 2024

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) will release its earnings data after the market closes on Wednesday, November 13th. Analysts expect Adaptimmune Therapeutics to post earnings of ($0.17) per share for the quarter.

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported $0.27 EPS for the quarter. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. The business had revenue of $128.23 million for the quarter, compared to analyst estimates of $58.00 million. On average, analysts expect Adaptimmune Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptimmune Therapeutics Trading Up 2.6 %

Shares of ADAP opened at $0.80 on Friday. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $0.92 and a 200 day moving average price of $1.05. Adaptimmune Therapeutics has a 12-month low of $0.42 and a 12-month high of $2.05. The firm has a market capitalization of $203.80 million, a P/E ratio of -2.28 and a beta of 2.26.

Analysts Set New Price Targets

ADAP has been the topic of a number of recent analyst reports. StockNews.com upgraded Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th.

Check Out Our Latest Stock Analysis on ADAP

Adaptimmune Therapeutics Company Profile

(Get Free Report)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.